Pattraporn Tajarernmuang
Overview
Explore the profile of Pattraporn Tajarernmuang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saeteng S, Chewaskulyong B, Charoentum C, Lertprasertsuke N, Euathrongchit J, Tajarernmuang P, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274489
: The prolonged time to reach investigation and management decisions in non-small cell lung cancer (NSCLC) patients can negatively impact long-term outcomes. This retrospective cohort study aims to assess the...
2.
Ngamsutham T, Chaiwong W, Dacha S, Sitilertpisan P, Pothirat C, Duangjit P, et al.
Tuberc Respir Dis (Seoul)
. 2024 Aug;
87(4):532-542.
PMID: 39139078
Background: The sequelae of post-coronavirus disease 2019 (COVID-19) pneumonia on lung function, exercise capacity, and quality of life were observed in both shortterm and long-term. However, the study about the...
3.
Mueankwan S, Trongtrakul K, Tajarernmuang P, Niyatiwatchanchai N, Kusirisin P, Narongkiatikhun P
J Clin Med
. 2024 Jun;
13(12).
PMID: 38929889
Hemoperfusion (HP) is employed to modulate cytokine storms in severe coronavirus disease 2019 (COVID-19) patients, requiring careful attention for success and safety. Therefore, we investigated whether our care bundles could...
4.
Trongtrakul K, Tajarernmuang P, Limsukon A, Theerakittikul T, Niyatiwatchanchai N, Surasit K, et al.
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202305
(1) Background: Early identification of severe coronavirus disease 2019 (COVID-19) pneumonia at the initial phase of hospitalization is very crucial. To address this, we validated and updated the National Early...
5.
Chaiwong W, Deesomchok A, Pothirat C, Liwsrisakun C, Duangjit P, Bumroongkit C, et al.
J Thorac Dis
. 2023 Oct;
15(9):4725-4735.
PMID: 37868845
Background: The sequelae of post-coronavirus disease 2019 (COVID-19) have been widely reported. However, the time point of the follow-up time in the previous studies varied ranging from 3-24 months and...
6.
Tajarernmuang P, Aliaga F, Alwakeel A, Tavaziva G, Turner K, Menzies D, et al.
Chest
. 2023 Sep;
165(2):461-474.
PMID: 37739030
Background: Programmed cell death ligand-1 (PD-L1) expression on tumor cells, evaluated by immunohistochemistry, guides the use of immunotherapy in advanced non-small cell lung cancer (NSCLC). Research Question: What is the...
7.
Tajarernmuang P, Valenti D, Gonzalez A, Artho G, Tsatoumas M, Beaudoin S
Qual Manag Health Care
. 2023 Aug;
33(3):206-212.
PMID: 37651595
Background And Objectives: Small chest drains are used in many centers as the default drainage strategy for various pleural effusions. This can lead to drain overuse, which may be harmful....
8.
Chaiwong W, Takheaw N, Pata S, Laopajon W, Duangjit P, Inchai J, et al.
Vaccine
. 2023 Aug;
41(40):5901-5909.
PMID: 37599143
Background: Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined...
9.
Deesomchok A, Liwsrisakun C, Chaiwong W, Pothirat C, Duangjit P, Bumroongkit C, et al.
Healthcare (Basel)
. 2023 Jul;
11(13).
PMID: 37444797
Many studies have demonstrated poor quality of life (QoL) at 3, 6, 12, and 24 months after coronavirus disease 2019 (COVID-19). However, these studies were limited due to cross-sectional design,...
10.
Takheaw N, Liwsrisakun C, Laopajon W, Pata S, Chaiwong W, Inchai J, et al.
Heliyon
. 2023 Apr;
9(4):e15653.
PMID: 37095993
The outbreak of the SARS-CoV-2 Omicron variant raised the need for vaccine boosting. We evaluated the efficiency of the third booster vaccine, ChAdOx-1 or BNT162b2, in causing a neutralizing antibody...